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Conclusions: Ivabradine improves clinical outcomes in heart
failure through a reduction in heart rate.
Perspective: The authors demonstrate improved outcomes in
heart failure with ivabradine, a negative chronotropic agent
that works at the sinus node. However, a significant interac-
tion was found between ivabradine and baseline heart rate,
suggesting ivabradine is most effective in those with baseline
heart rates >77 bpm. A companion paper in Lancet demon-
strated lower baseline beta-blocker and angiotensin-
converting enzyme inhibitor administration to those heart
failure patients with higher heart rates. If these subjects were
truly intolerant of higher beta-blocker doses, ivabradine may
have a beneficial role for such patients with heart failure.   
Summary written by: Jennifer Cowger, MD
Guidelines for the Management of Atrial
Fibrillation: The Task Force for the Management
of Atrial Fibrillation of the European Society of
Cardiology (ESC)
Camm AJ, Kirchof P, Lip GY, et al.
Eur Heart J 2010;Aug 29:[Epub ahead of print].
Perspective: The following are 10 points to remember from
the guidelines for atrial fibrillation (AF) management from
the European Society of Cardiology:  
1: Left ventricular function often is impaired by AF because
of rhythm irregularity, a rapid ventricular rate, loss of atrial
contractile function, loss of atrioventricular synchrony, and
elevated left ventricular filling pressure.
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Arrhythmias
Ivabradine and Outcomes in Chronic Heart Failure
(SHIFT): A Randomised Placebo-Controlled Study
Swedberg K, Komajda M, Bohm M, et al., on behalf of the SHIFT
Investigators.
Lancet 2010;376:875–885.
Study Question: Does ivabradine reduce adverse events in sys-
tolic heart failure?
Methods: This was a randomized, double-blind, controlled trial
of ivabradine versus placebo administered to subjects with sta-
ble symptomatic (4 weeks) heart failure with at least one heart
failure admission in 12 months, a baseline heart rate >70
bpm, on optimal medical management. The primary endpoint
was time to first event for cardiovascular death or heart failure
admission.
Results: At baseline, there were no significant differences
between patients randomized to ivabradine (n = 3,241) or
placebo (n = 3,264). At 28 days and 1 year, mean heart rate
dropped by 10.9 and 9.1 bpm, respectively, compared with
placebo. Patients treated with ivabradine had an 18% reduc-
tion (hazard ratio [HR], 0.82) in the hazard for death,
yielding a number needed to treat of 26 patients over 1 year.
This improvement in outcome was mainly driven by a reduc-
tion in hospital admissions for heart failure (HR, 0.74) and
heart failure (but not all-cause) death (HR, 0.74). Treatment
effect appeared to be restricted to those with baseline heart
rates >77 bpm. Adverse events from the drug were low.
SCANNING THE LITERATURE
Summaries of Key Journal Articles
Kim A. Eagle, MD, Editor-in-Chief, Journal Scan, Ann Arbor, MI
Christopher P. Cannon, MD, Editor-in-Chief, Cardiosource, Boston, MA
William F. Armstrong, MD, Ann Arbor, MI, David S. Bach, MD, Ann Arbor, MI, Ragavendra R.
Baliga, MBBS, Columbus, OH, Anna M. Booher, MD, Ann Arbor, MI, Timothy B. Cotts, MD, 
Ann Arbor, MI, Jennifer Cowger, MD, Ann Arbor, MI, Daniel T. Eitzman, MD, Ann Arbor, MI, 
James B. Froehlich, MD, Ann Arbor, MI, Caren S. Goldberg, MD, Ann Arbor, MI, Hitinder S. Gurm,
MBBS, Ann Arbor, MI, Jennifer C. Hirsch, MD, Ann Arbor, MI, Elizabeth Anne Jackson, MD, 
Ann Arbor, MI, Fred Morady, MD, Ann Arbor, MI, Debabrata Mukherjee, MD, El Paso, TX,
Himanshu J. Patel, MD, Ann Arbor, MI, John E. Rectenwald, MD, MS, Ann Arbor, MI, Melvyn
Rubenfire, MD, Ann Arbor, MI, Associate Editors, Cardiosource
4.0%). The in-hospital mortality after medical management
was significantly increased in group I compared with group
II (35.6% vs. 1.5%). Mortality rates after surgical (20% vs.
28%) or endovascular management (3.7% vs. 9.1%) did not
differ significantly between groups I and II, respectively. A
multivariable logistic regression model confirmed that recur-
rent and/or refractory pain or refractory hypertension was a
predictor of in-hospital mortality (odds ratio, 3.31; 95%
confidence interval, 1.04-10.45).
Conclusions: Recurrent pain and refractory hypertension
appeared as clinical signs associated with increased in-hospi-
tal mortality in patients with acute aortic dissection,
particularly when managed medically.
Perspective: This study suggests that ABAD patients present-
ing with refractory hypertension and/or pain symptoms, in
the absence of other complications, are at intermediate risk
for an adverse in-hospital outcome. These observations sug-
gest that aortic intervention, such as via an endovascular
approach, may be appropriate in this intermediate-risk
group of patients with ABAD.  
Summary written by: Debabrata Mukherjee, MD
Congenital Heart Disease
ESC Guidelines for the Management of Grown-up
Congenital Heart Disease (new version 2010): The
Task Force on the Management of Grown-up
Congenital Heart Disease of the European Society
of Cardiology (ESC) 
Baumgartner H, Bonhoeffer P, De Groot NM, et al.
Eur Heart J 2010;Aug 27:[Epub ahead of print].
Perspective: The following are 10 points to remember from the
updated European Society of Cardiology guidelines for the
management of adult congenital heart disease:
1: Cardiac magnetic resonance imaging is an important
technique for the evaluation of adults with congenital heart
disease. It is particularly important for quantification of
right ventricular size and function; quantification of pul-
monary insufficiency; evaluation of extracardiac structures
including the pulmonary arteries, veins, and the aorta; and
detection of myocardial fibrosis and scar.
2: Device closure is the preferred method for most atrial sep-
tal defects, and is indicated if signs of right ventricular
volume overload are present. Atrial septal defect closure
should be avoided in patients with Eisenmenger physiology. 
3: Patients with ventricular septal defects should be moni-
tored for long-term complications including endocarditis,
development of double-chambered right ventricle, subaortic
stenosis, and aortic insufficiency due to leaflet prolapse.
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2: Asymptomatic AF is common, even in patients with
symptomatic AF, and this has important implications for
discontinuation of antithrombotic therapy.
3: The risk of stroke is dictated by risk factors and is inde-
pendent of whether the AF is paroxysmal or persistent.
4: The relative efficacy of aspirin to prevent stroke decreases
with age, whereas that of warfarin does not.  
5: Warfarin is recommended in the presence of >1 of the fol-
lowing risk factors: heart failure, hypertension, age ≥75 years,
diabetes, and prior stroke/embolism.
6: The decision to use aspirin or warfarin in the presence of
one of the above risk factors should be individualized.
7: The combination of aspirin and clopidogrel is more effec-
tive than aspirin for stroke prevention, but not as effective as
warfarin.
8: The “pill-in-the-pocket” approach should be considered for
patients without structural heart disease who have relatively
infrequent episodes of symptomatic AF.
9: Before choosing a long-term rate-control strategy, symp-
toms attributable to AF and factors that influence the efficacy
of rhythm control should be considered.
10: In a recent meta-analysis, catheter ablation of AF had a
1-year success rate of 77% compared to 52% for antiarrhyth-
mic drug therapy.
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Importance of Refractory Pain and Hypertension in
Acute Type B Aortic Dissection. Insights From the
International Registry of Acute Aortic Dissection
(IRAD)
Trimarchi S, Eagle KA, Nienaber CA, et al.
Circulation 2010;122:1283–1289.
Study Question: What is the impact of refractory pain and/or
refractory hypertension on the outcomes of acute type B
aortic dissection (ABAD)? 
Methods: Three hundred sixty-five patients affected by
uncomplicated ABAD, enrolled in the International
Registry of Acute Aortic Dissection (IRAD) from 1996 to
2004, were categorized according to risk profile into two
groups. Patients with recurrent and/or refractory pain or
refractory hypertension (group I; n = 69) and patients with-
out clinical complications at presentation (group II; n = 296)
were compared.
Results: The overall in-hospital mortality was 6.5% and was
increased in group I compared with group II (17.4% vs.
completing the trial phase, patients were invited to enroll in
a cohort phase in which the blood pressure target was less
than 130/80 mm Hg. The primary clinical outcome in the
cohort phase was the progression of chronic kidney disease,
defined as a doubling of the serum creatinine level, diagnosis
of end-stage renal disease (ESRD), or death. Follow-up
ranged from 8.8 to 12.2 years.
Results: During the trial phase, the mean blood pressure was
130/78 mm Hg in the intensive-control group and 141/86
mm Hg in the standard-control group. During the cohort
phase, corresponding mean blood pressures were 131/78 and
134/78 mm Hg. In both phases, there was no significant
between-group difference in the risk of the primary outcome
(hazard ratio in the intensive-control group, 0.91; p = 0.27).
However, the effects differed according to the baseline level of
proteinuria (p = 0.02 for interaction), with a potential benefit
in patients with a protein-to-creatinine ratio of more than
0.22 (hazard ratio, 0.73; p = 0.01).
Conclusions: Intensive blood pressure control had no effect on
kidney disease progression.
Perspective: In the study patients with a protein-to-creatinine
ratio of more than 0.22, intensive blood pressure control sig-
nificantly retarded disease progression, as well as outcomes
directly related to chronic kidney disease and clinical out-
comes (ESRD or death). This study supports a lower blood
pressure target in black patients with chronic kidney disease
and proteinuria, but suggests that patients without proteinuria
may have no benefit from intensive blood pressure control.  
Summary written by: Debabrata Mukherjee, MD
Rimonabant for Prevention of Cardiovascular
Events (CRESCENDO): A Randomised, Multicentre,
Placebo-Controlled Trial 
Topol EJ, Bousser MG, Fox KA, et al., on behalf of the CRESCENDO
Investigators.
Lancet 2010;376:517–523.
Study Question: What is the effect of blockade of the endo-
cannabinoid receptor with rimonabant on major vascular
event-free survival?
Methods: This double-blind, placebo-controlled trial was
undertaken in 974 hospitals in 42 countries. A total of
18,695 patients with previously manifest or increased risk of
vascular disease were randomly assigned to receive either
rimonabant 20 mg (n = 9,381) or matching placebo (n =
9,314). Randomization was stratified by centre, imple-
mented with an independent interactive voice response
system, and all study personnel and participants were
masked to group assignment.
Results: At a mean follow-up of 13.8 months, the trial was
prematurely discontinued because of concerns by health
4: Percutaneous closure of patent ductus arteriosus is appro-
priate when left ventricular volume overload is present.
Closure of a “silent ductus” is not indicated. Closure of
patent ductus arteriosus is not appropriate in the setting of
Eisenmenger physiology.
5: Patients with repaired coarctation of the aorta are at risk
for multiple long-term complications including arterial hyper-
tension, recurrent coarctation, aneurysms of the ascending
aorta or coarctation repair site, premature coronary artery dis-
ease, and berry aneurysms of the circle of Willis.
6: Indications for intervention in adults with coarctation of
the aorta include a noninvasive pressure difference ≥20 mm
Hg between the upper and lower extremities with upper
extremity hypertension, pathologic blood pressure response
to exercise, and significant left ventricular hypertrophy.
7: All patients with tetralogy of Fallot should be seen at a
specialized adult congenital heart program. The presence or
absence of pulmonary insufficiency must be determined.
Pulmonary valve replacement (PVR) should be performed in
symptomatic patients with severe pulmonary insufficiency
for stenosis and in some asymptomatic patients. 
8: All patients with single-ventricle physiology following the
Fontan procedure should be seen at an adult congenital cen-
ter. Long-term complications include progressive heart
failure, cyanosis, development of atrial arrhythmias, chronic
venous insufficiency, and protein losing enteropathy.
9: Patients with a Rastelli procedure, pulmonary atresia, com-
mon arterial trunk, and previous Ross operation will have had
a conduit placed between the right ventricle and pulmonary
arteries. Such patients are now candidates for percutaneous
PVR when conduit insufficiency or stenosis develops.
10: Bosentan should be initiated in patients with Eisenmenger
syndrome who are World Health Organization-Functional
Class III. Patients with Eisenmenger require meticulous fol-
low-up and avoidance of high-risk states.   
Summary written by: Timothy B. Cotts, MD
General Cardiology
Intensive Blood-Pressure Control in Hypertensive
Chronic Kidney Disease
Appel LJ, Wright JT Jr, Greene T, et al.
N Engl J Med 2010;363:918–929.
Study Question: What is the effect of intensive blood pressure
control on the progression of chronic kidney disease among
black patients?  
Methods: The investigators randomly assigned 1,094 black
patients with hypertensive chronic kidney disease to receive
either intensive or standard blood pressure control. After
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regulatory authorities in three countries about suicide in
individuals receiving rimonabant. All randomized partici-
pants were analyzed. At the close of the trial (November
2008), the composite primary endpoint of cardiovascular
death, myocardial infarction, or stroke occurred in 364
(3.9%) patients assigned to rimonabant and 375 (4.0%)
assigned to placebo (p = 0.68). With rimonabant, gastroin-
testinal (3,038 [33%] vs. 2,084 [22%]), neuropsychiatric
(3,028 [32%] vs. 1,989 [21%]), and serious psychiatric side
effects (232 [2.5%] vs. 120 [1.3%]) were significantly
increased compared with placebo. Four patients in the
rimonabant group and one in the placebo group committed
suicide.
Conclusions: The premature termination of this trial has
important lessons for drug development.
Perspective: Although this trial was underpowered with the
prespecified goal, the absence of any reduction of cardiovas-
cular endpoints, despite the anticipated benefit in metabolic
parameters, is disappointing. The experience and data from
the abrupt termination of this clinical trial, due to serious
neuropsychiatric side effects, will hopefully prove useful in
planning future drug development.  
Summary written by: Debabrata Mukherjee, MD
Dose Comparisons of Clopidogrel and Aspirin in
Acute Coronary Syndromes 
The CURRENT–OASIS 7 Investigators.
N Engl J Med 2010;363:930–942. 
Study Question: What is the ideal dose of aspirin and clopido-
grel in patients with acute coronary syndromes (ACS)? 
Methods: The authors randomized 25,086 patients with ACS
who were referred for an invasive strategy, in a 2 x 2 factorial
design, to either double-dose clopidogrel (a 600 mg loading
dose on day 1, followed by 150 mg daily for 6 days and 75
mg daily subsequently) or standard-dose clopidogrel (a 300
mg loading dose and 75 mg daily) and either higher-dose
aspirin (300-325 mg daily) or lower-dose aspirin (75-100 mg
daily). The primary outcome was cardiovascular death,
myocardial infarction, or stroke at 30 days.
Results: There was no difference in the primary endpoint
between patients randomized to double-dose clopidogrel
(4.2%) compared with standard-dose clopidogrel (4.4%; p =
0.30). Higher-dose clopidogrel was associated with increase in
major bleeding (2.5% vs. 2.0%; p = 0.01). There was a signifi-
cant reduction in stent thrombosis with double-dose
clopidogrel among the 17,263 patients who underwent percu-
taneous coronary intervention (PCI) (1.6% vs. 2.3%; p =
0.001). There was no significant difference between higher-
and lower-dose aspirin with respect to the primary outcome
(4.2% vs. 4.4%, p = 0.61) or major bleeding (2.3% vs. 2.3%, p
= 0.90). 
Conclusions: There was no difference between high- and low-
dose aspirin or standard- and double-dose clopidogrel with
respect to the primary outcome in patients with ACS.
Perspective: This interesting study suggests that either dose can
be used. However, among patients undergoing PCI, there was
a reduction in the primary endpoint (3.9% vs. 4.5%, p =
0.039), whereas there was an increase in bleeding events (1.6%
vs. 1.1%) (Mehta SR, et al. Lancet 2010;Sep 1:[Epub ahead of
print]). These data suggest that double-dose clopidogrel
should be reserved for patients at high risk for stent thrombo-
sis and low risk of bleeding, and only the standard dose should
be used in patients with ACS who do not undergo PCI.  
Summary written by: Hitinder S. Gurm, MBBS
Comparative Determinants of 4-Year
Cardiovascular Event Rates in Stable Outpatients
at Risk of or With Atherothrombosis 
Bhatt DL, Eagle KA, Ohman EM, et al., on behalf of the REACH
Registry Investigators.
JAMA 2010;Aug 30:[Epub ahead of print].
Study Question: Can the relative risk of cardiovascular events
in stable outpatients with various initial manifestations of
atherothrombosis be performed using simple clinical
descriptors?
Methods: Outpatients with coronary artery disease, cerebrovas-
cular disease, peripheral arterial disease, or patients at least 45
years old with three or more risk factors for atherothrombosis
were enrolled in the global Reduction of Atherothrombosis
for Continued Health (REACH) Registry. Patients from
3,647 centers in 29 countries were enrolled between 2003 and
2004 and followed up until 2008.
Results: A total of 45,227 patients with baseline data were
included. Mean age was 68.4 years, 65% were men, 16% were
smokers, 81% had hypertension, and 44% had diabetes.
Treatment use during the 4 years included ≥1 antithrombotic
in 88%; ≥1 hypoglycemic in 87% of diabetics; statins in 73%;
angiotensin-converting enzyme inhibitors or angiotensin-
receptor blockers in 69%, and beta-blockers in 51%. During
the follow-up period, 5,481 patients experienced at least one
event, including 2,315 with cardiovascular death, 1,228 with
myocardial infarction, 1,898 with stroke, and 40 with both a
myocardial infarction and stroke on the same day. Among
patients with atherothrombosis, those with a prior history of
ischemic events at baseline (n = 21,890) had the highest rate
of subsequent ischemic events (18.3%); patients with stable
coronary, cerebrovascular, or peripheral artery disease (n =
15,264) had a lower risk (12.2%); and patients without estab-
lished atherothrombosis, but with risk factors only (n = 8,073)
had the lowest risk (9.1%). 
Conclusions: Clinical descriptors can assist clinicians in identi-
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ence to antihypertensive medication was effective in improv-
ing both adherence and blood pressure control.
Perspective: No effects were found on cardiovascular morbid-
ity and mortality, but the study was not adequately powered
for these outcomes. The intervention did increase the aver-
age length of an office visit by ~7 minutes, which may be
difficult in some busy clinical settings. Additional larger
studies are indicated to assess the relative importance of vari-
ous components of this intervention, including a potential
Hawthorne effect and effects of the intervention on cardio-
vascular endpoints.  
Summary written by: Debabrata Mukherjee, MD
Patients’ and Cardiologists’ Perceptions of the
Benefits of Percutaneous Coronary Intervention
for Stable Coronary Disease
Rothberg MB, Sivalingam SK, Ashraf J, et al.
Ann Intern Med 2010;153:307–313.
Study Question: Do cardiologists and patients have similar
beliefs about the benefit of percutaneous coronary intervention
(PCI)?  
Methods: The authors surveyed 153 patients who consented to
elective coronary catheterization and possible PCI, 10 inter-
ventional cardiologists, and 17 referring cardiologists on their
belief regarding perceived benefits of PCI. All cardiologists
also answered questions on reported benefit of PCI in hypo-
thetical scenarios. Interventional cardiologists also reported on
perceived benefit of intervention for study patients who under-
went PCI.
Results: Angina was present in 68% of the 153 patients, and
was activity limiting in 42%. PCI was performed in 53
patients, of whom 75% had angina. The majority of patients
thought that PCI would reduce their risk of mortality and
myocardial infarction (MI). Patients were significantly more
likely than physicians to believe that PCI would prevent MI
(prevalence ratio, 4.25) or fatal MI (prevalence ratio, 4.83).
For the hypothetical scenarios, 63% of cardiologists believed
that the benefits of PCI were limited to symptom relief. 
Conclusions: Most patients (but not cardiologists) believe that
PCI for stable angina will be associated with a reduction in
the risk of MI or death.
Perspective: This is an interesting study that vividly demon-
strates the disconnect in the informed consent process. This
study corroborates prior work and invokes the need for better
structured and validated methods to inform patients of the risk
and benefits of PCI and other procedures.  
Summary written by: Hitinder S. Gurm, MBBS
fying high-risk patients within the broad range of risk for
outpatients with atherothrombosis.
Perspective: The study results offer clinicians an easy way to
risk stratify patients with complex medical problems. That
the event rate varied from <2% annually in those high risk
without diabetes to 6.25% or threefold in those with poly-
vascular disease, should not deter physicians from being
vigilant about providing recommendations for lifestyle
changes and evidence-based treatments to all persons with
characteristics of those in REACH. The ability to easily
identify the very high risk groups from the REACH data set
will provide a simple way for investigators to design future
studies of novel untested therapies.  
Summary written by: Melvyn Rubenfire, MD
Multicenter Cluster-Randomized Trial of a
Multifactorial Intervention to Improve
Antihypertensive Medication Adherence and Blood
Pressure Control Among Patients at High
Cardiovascular Risk (The COM99 Study) 
Pladevall M, Brotons C, Gabriel R, et al., on behalf of the Writing
Committee on behalf of the COM99 Study Group.
Circulation 2010;122:1183–1191. 
Study Question: How effective is a multifactorial intervention
to improve both medication adherence and blood pressure
control and to reduce cardiovascular events?
Methods: In this multicenter, cluster-randomized trial, physi-
cians from hospital-based hypertension clinics and primary
care centers across Spain were randomized to receive and pro-
vide the intervention to their high-risk patients. Eligible
patients were ≥50 years of age, had uncontrolled hyperten-
sion, and had an estimated 10-year cardiovascular risk >30%.
Physicians randomized to the intervention group counted
patients’ pills, designated a family member to support adher-
ence behavior, and provided educational information to
patients. The primary outcome was blood pressure control at
6 months. Secondary outcomes included both medication
adherence and a composite endpoint of all-cause mortality
and cardiovascular-related hospitalizations.
Results: Seventy-nine physicians and 877 patients partici-
pated in the trial. The mean duration of follow-up was 39
months. Intervention patients were less likely to have an
uncontrolled systolic blood pressure (odds ratio, 0.62; 95%
confidence interval, 0.50-0.78) and were more likely to be
adherent (odds ratio, 1.91; 95% confidence interval, 1.19-
3.05) than controls at 6 months. After 5 years, 16% of
patients in the intervention and 19% in the control group
met the composite endpoint (hazard ratio, 0.97; 95% confi-
dence interval, 0.67-1.39). 
Conclusions: A multifactorial intervention to improve adher-
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Efficacy and Safety of Dabigatran Compared With
Warfarin at Different Levels of International
Normalized Ratio Control for Stroke Prevention in
Atrial Fibrillation: An Analysis of the RE-LY Trial
Wallentin L, Yusuf S, Ezekowitz MD, et al., on behalf of the RE-LY
Investigators.
Lancet 2010;376:975–983.
Study Question: Does the time in therapeutic range (TTR)
affect the efficacy of warfarin relative to dabigatran?
Methods: This was a post-hoc analysis of the RE-LY trial, in
which 18,024 patients with atrial fibrillation randomly
received 110 or 150 mg of dabigatran twice daily or warfarin
dose-adjusted to achieve an international normalized ratio of
2-3. The TTRs for individual centers (cTTRs) were calcu-
lated by averaging the TTRs for individual patients at that
center. Outcomes were compared by quartiles of cTTR.
Results: The annual rate of stroke and systemic embolism
was reduced from 1.7% in the warfarin group to 1.5% in the
110 mg dabigatran group and 1.1% in the 150 mg dabiga-
tran group. The quartiles of cTTR were <57.1%,
57.1-65.5%, 65.5-72.6%, and >72.6%. There was no inter-
action between the stroke/embolism rate and cTTR at either
dose of dabigatran versus warfarin. The annual rate of hem-
orrhagic stroke was reduced from 0.4% in the warfarin
group to 0.1% in the 110 and 150 mg dabigatran groups,
with no interaction with cTTR. The annual rate of major
bleeds was lower in the 110 mg dabigatran (2.9%) than the
warfarin (3.6%) or the 150 mg dabigatran group (3.3%).
There was significant interaction between cTTR and major
bleeds when comparing 150 mg dabigatran to warfarin, and
between cTTR and cardiovascular events and total mortality
in both dabigatran groups versus warfarin.
Conclusions: The extent of benefit of dabigatran versus war-
farin depends on the TTR.
Perspective: A striking finding is that the TTR was <65% in
one-half of the patients, even in a clinical trial.  
Summary written by: Fred Morady, MD
Heart Failure/Transplant
Heart Rate as a Risk Factor in Chronic Heart
Failure (SHIFT): The Association Between Heart
Rate and Outcomes in a Randomised Placebo-
Controlled Trial
Bohm M, Swedberg K, Komajda M, et al.
Lancet 2010;376:886–894.
Study Question: Is heart rate a risk factor for cardiovascular
events in heart failure (HF)?
Methods: This was a secondary analysis of the SHIFT cohort,
which included patients with symptomatic HF (left ventric-
ular ejection fraction ≤35%), one prior admission in 12
months, and a heart rate >70 bpm at baseline who were ran-
domized to ivabradine (n = 3,241) or placebo (n = 3,264).
Subjects were divided into quintiles based on heart rates in
the placebo group, and adjusted hazard ratios (HR, 95%
confidence interval) for cardiovascular death or hospitaliza-
tion for HF (composite endpoint) were calculated using the
lowest heart quintile as the reference.
Results: For every beat increase in heart rate, risk for
death/hospitalization increased 3% in the placebo group.
The HR for death/HF hospitalization in placebo patients
with heart rates ≥87 bpm, 80-87 bpm, and 75-80 bpm was
2.34 (1.84-2.98), 1.80 (1.4-2.31), 1.33 (1.03-1.70) fold
higher, respectively, than patients with heart rates of 70-72
bpm. Subjects in the ivabradine group had lower heart rates
than placebo patients after 28 days of therapy. After adjust-
ing for change in heart rate at 28 days and baseline risk,
ivabradine had no impact on the hazard (HR, 0.95 [0.85-
1.06]) of death/hospitalization compared with placebo.
Conclusions: An elevated heart rate is a risk factor for HF
events and ivabradine improved outcomes mainly through a
reduction in heart rate.
Perspective: This substudy helps elucidate findings from the
main SHIFT study, which showed a reduction in
death/hospitalization following ivabradine therapy in HF.
The study does not meet statistical criteria to establish ‘risk,’
but does suggest an association between higher heart rate
and poorer HF outcomes. It is not clear if those with higher
heart rates had worse outcomes because they were under-
treated with evidence-based medicine or if they were just
‘sicker’ in general. Because it does not appear that lowering
heart rate had a negative impact on outcome, it suggests the
former may be true.
Summary written by: Jennifer Cowger, MD
2010 Focused Update of ESC Guidelines on Device
Therapy in Heart Failure: An Update of the 2008
ESC Guidelines for the Diagnosis and Treatment of
Acute and Chronic Heart Failure and the 2007
ESC Guidelines for Cardiac and Resynchronization
Therapy
Dickstein K, Vardas PE, Auricchio A, et al.
Eur Heart J 2010;Aug 27:[Epub ahead of print].
Perspective: The following are 10 points to remember from the
updated guidelines on device therapy in heart failure:
1: This document provides an update on the recommenda-
tions established by the Committee for Practice Guidelines
(CPG) of the European Society of Cardiology (ESC) for
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device therapy in heart failure.
2: Cardiac resynchronization therapy (CRT) is recom-
mended for New York Heart Association (NYHA) class III
and IV patients with a left ventricular ejection fraction
(LVEF) ≤35%, QRS ≥120 ms, in sinus rhythm, and on
optimal medical management.
3: In subjects with NYHA class III/IV heart failure, CRT
with defibrillator (CRT-D) therapy should be considered in
those with good functional status and a survival estimate >1
year.
4: Studies examining the impact of CRT in patients with
NYHA class I heart failure are limited, and the ESC does
not recommend CRT in patients with no or transient mild
heart failure symptoms.
5: Based on results of the MADIT-CRT and REVERSE
trials, CRT or CRT-D is recommended for patients with
NYHA class II symptoms, LVEF ≤35%, QRS ≥150 ms, in
sinus rhythm, and on optimal medical management.
6: In patients with borderline QRS intervals (120-150 ms),
other criteria should be considered when assessing for CRT
benefit, including presence of dyssynchrony or LV dilation
on echocardiography, a left bundle branch block (LBBB)
pattern on electrocardiogram, a nonischemic etiology for
cardiomyopathy, or recent NYHA class III symptoms.
7: The CPG-ESC acknowledged that data on CRT in sub-
jects with heart failure and permanent or persistent atrial
fibrillation are limited despite their arrhythmic burden.
CRT or CRT-D therapy in these subjects should be
restricted to those with NYHA class III/IV heart failure
with an LVEF ≤35%, QRS ≥130 ms, on optimal medical
management, who are pacemaker dependent or with fre-
quent ventricular pacing (≥95% pacing).
8: In subjects with permanent or persistent atrial fibrillation,
there is presently insufficient evidence for mortality reduc-
tion with CRT/CRT-D. Evidence is strongest for those
with LBBB pattern. Atrial fibrillation rate control is impor-
tant to ensure adequate biventricular pacing.
9: CRT/CRT-D may be considered in those with a QRS
<120 ms and a class I indication for a standard pacemaker
who have NYHA class II or III/IV heart failure, to maintain
intrinsic or near normal ventricular activation.
10: LV assist device support may be considered as perma-
nent therapy in subjects ineligible for cardiac transplant who
have NYHA class IIIb/IV heart failure, LVEF ≤25%, and
measured peak VO2 <14 ml/kg/min on cardiopulmonary
stress testing.
Summary written by: Jennifer Cowger, MD
Interventional Cardiology
J-Curve Revisited: An Analysis of Blood Pressure
and Cardiovascular Events in the Treating to New
Targets (TNT) Trial
Bangalore S, Messerli FH, Wun CC, et al., on behalf of the Treating
to New Targets Steering Committee and Investigators.
Eur Heart J 2010;Sep 16:[Epub ahead of print].
Study Question: In patients with coronary artery disease (CAD),
a J-curve relationship has been reported between blood pres-
sure (BP) and future cardiovascular events. What is the
relationship between BP and cardiovascular outcomes in
patients with CAD participating in a non-BP clinical trial? 
Methods: The TNT study of 10,001 patients with CAD was
utilized to assess the impact of BP on cardiovascular events.
Patients with a low-density lipoprotein (LDL) cholesterol
level <130 mg/dl were randomized to atorvastatin 80 versus 10
mg. The post-baseline, time-dependent BPs (systolic blood
pressure [SBP] and diastolic blood pressure [DBP]) were cate-
gorized into 10 mm Hg increments. The primary outcome
was a composite of death from coronary disease, nonfatal
myocardial infarction (MI), resuscitated cardiac arrest, and
fatal or nonfatal stroke.
Results: At median 4.9 years of follow-up, 982 (9.82%)
patients experienced a primary outcome. The relationship
between SBP or DBP and primary outcome followed a J-
curve with increased event rates above and below the reference
BP range, both unadjusted and adjusted (for baseline covari-
ates, treatment effect, and LDL levels). A time-dependent,
nonlinear, multivariate Cox proportional hazard model identi-
fied a nadir of 146.3/81.4 mm Hg where the event rate was
lowest. A similar nonlinear relationship with a higher risk of
events at lower pressures was found for most of the secondary
outcomes of all-cause mortality, cardiovascular mortality, non-
fatal MI, or angina. However, for the outcome of stroke,
lower was better for SBP. 
Conclusions: In patients with CAD, a low BP (<110-120/<60-
70 mm Hg) portends an increased risk of future cardiovascular
events (except stroke). 
Perspective: In the TNT trial, the curve was U-shaped with
evidence that optimal pressure was about 140/80 mm Hg,
with a similar increase in hazard ratio (~0.4) for a SBP <120
mm Hg and >175 mm Hg. While the clinical parameters
associated with a lower BP appeared to be risk factors for rela-
tive hypotension, the only significant interaction of SBP was
with prior bypass surgery. Those with prior bypass surgery had
higher event rates at low SBP compared with those without,
and patients with prior bypass surgery tolerated higher SBPs.
Summary written by: Melvyn Rubenfire, MD
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Prognostic and Therapeutic Implications of
Pulmonary Hypertension Complicating Degenerative
Mitral Regurgitation due to Flail Leaflet: A
Multicenter Long-Term International Study
Barbieri A, Bursi F, Grigioni F, et al.; on behalf of the Mitral
Regurgitation International DAtabase (MIDA) Investigators.
Eur Heart J 2010;Sep 8:[Epub ahead of print].
Study Question: What are the frequency, predictors, and out-
come implications of pulmonary artery hypertension (PAH)
diagnosed by Doppler echocardiography in patients with
degenerative mitral regurgitation (MR) due to flail leaflet?
Methods: MIDA is a registry of patients with MR due to flail
leaflet referred to selected tertiary care centers in Europe and
the United States. Between 1987 and 2004, pulmonary artery
systolic pressure (PASP) was measured at baseline by Doppler
echocardiography in 437 patients (ages 67 ± 11 years; 66%
men). Pulmonary artery hypertension (PAH; defined as PASP
>50 mm Hg) was observed in 102 patients (23%). 
Results: Independent predictors of PAH were age and left
atrial size (p < 0.0001). During a mean follow-up of 4.8 ± 2.8
years, PAH was a strong independent predictor of death
(adjusted hazard ratio [HR], 2.03), cardiovascular death
(CVD; adjusted HR, 2.21), and heart failure (adjusted HR,
1.70). Although mitral valve surgery at any time during fol-
low-up (performed in 325 patients, 75%) was beneficial
(adjusted HR for death, 0.22), PAH was associated with an
increased risk of postoperative death and CVD (p = 0.01).
Conclusions: PAH is a frequent complication of MR due to flail
leaflet, and is associated with adverse outcomes, approximately
doubling the risk of death and heart failure after diagnosis.
Mitral valve surgery performed during follow-up is beneficial
in both patients with and without PAH, although surgery
does not abolish the adverse effects associated with PAH.
These data support relieving PAH secondary to MR caused by
flail leaflet, as well as consideration for mitral surgery before
PAH is established.
Perspective: Intervention for chronic severe MR prior to the
development of symptoms, dramatic left ventricular (LV) dila-
tion, LV systolic dysfunction, atrial fibrillation, or PAH is
associated with better clinical outcomes. If this philosophy is
embraced, the next challenge might be to assure that only
patients with severe MR are referred for early intervention.
Specifically, the presence of a pathologic consequence of MR
traditionally has served to assure that the MR is of hemody-
namic consequence. In light of the vagaries of quantifying
regurgitation severity using essentially any technique, care will
be necessary to avoid ‘early’ intervention on patients with less
than severe valve disease.
Summary written by: David S. Bach, MD
Contribution of Exercise Echocardiography to the
Diagnosis of Heart Failure With Preserved
Ejection Fraction (HFpEF)
Holland DJ, Prasad SB, Marwick TH.
Heart 2010;96:1024–1028.
Study Question: Is there an additional contribution from exer-
cise echocardiography (ExE) to the diagnosis of HFpEF?  
Methods: Data were available from 436 consecutive patients
referred for ExE for evaluation of fatigue or dyspnea in whom
a diagnosis of HFpEF was considered. The patients under-
went rest and ExE with evaluation of wall motion for
ischemia and E/e’. 
Results: By current European guidelines, HFpEF was consid-
ered present in 148 patients. On exercise testing, only 36 of
the 148 patients (24%) with clinically suspected HFpEF had
objective evidence of exercise intolerance. Patients with E/e’
>13 at rest had lower exercise capacity than those with E/e’
<13 (8.3 ± 2.5 vs. 10.3 ± 3.1 METs). An increase in E/e’ with
exercise was associated with a lower workload (8.7 ± 2.7 vs.
10.4 ± 3.1 METs). Of 148 patients with suspected HFpEF
by standard criteria, only 63 had elevated E/e’ at rest or with
exercise. An increase in exercise E/e’ was seen in only two
patients without evidence of rest diastolic dysfunction (1.5%).
Inducible ischemia was noted in 30% of patients with sus-
pected HFpEF. Of a total study population (n = 436), only
102 patients had evidence of elevated filling pressure at rest or
with exercise, 35 of whom had evidence of inducible
ischemia. After consideration of exercise capacity, only 13
patients remained, fitting a more strict criteria of HFpEF,
which required echocardiographic proof of raised filling pres-
sures, absence of ischemia, and objectively decreased exercise
tolerance. 
Conclusions: Current criteria for HFpEF include many patients
with preserved exercise tolerance, many with ischemia, and
many without true evidence of elevated filling pressures. 
Perspective: This study is intriguing in multiple respects, per-
haps most notable, that patients are often given a diagnosis of
HFpEF in the absence of any objective evidence of exercise
intolerance, and who were probably symptomatic related to
deconditioning or other noncardiac issues. Clearly, criteria for
the diagnosis of HFpEF should be strengthened, and objec-
tive evidence of both exercise intolerance and true cardiac
symptoms incorporated into the diagnosis.
Summary written by: William F. Armstrong, MD
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